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__________________________________________
Diabetes care provides a concrete model for the analysis of the relationship between
quality care and economic outcomes. There is now a significant body of research on
the factors that can produce positive clinical outcomes and the economic costs of
failing to meet specific treatment goals.1 A particularly productive approach is to
look at the clinical consequences and costs related to the loss of blood sugar control.
A lack of insulin or insulin effect leads to higher than normal levels of blood sugar
creating a state of glucose toxicity. It is the glucose toxicity that over a period of
time causes organ damage. It is glucose toxicity that makes diabetes the number
one cause of blindness, kidney failure and non-traumatic loss of limbs in the U.S.
Diabetes is a major factor in the development of heart attack and stroke. A diagnosis
of diabetes confers the same cardiac risk to a patient as does having a heart attack.
Simply put, a diagnosis of diabetes is the same as having a heart attack. Landmark
studies such as the DCCT (Diabetes Control and Complications Trial) and UKDPS (UK
Prospective Diabetes Study) have shown that controlling glucose toxicity mitigates
the complications of diabetes.
Hemoglobin A1C (HgbA1C) is a convenient measure of glucose toxicity. It measures
the amount of glucose that “sticks” to the pigment (hemoglobin) that makes blood
red. It correlates with the average blood sugar level that has been present during
the previous two to three months. The higher the hemoglobin A1C is the greater the
glucose toxicity and the greater the risk for diabetic complications.2,3 For example,
patients with HgbA1C of 9% have a five-fold increase in the risk for retinopathy
(damage to the light sensing portion of the eye) when compared to HgbA1C of 6%.
Lowering levels of blood sugar reduces this risk. Similarly, lowering the HgbA1C by
1% confers a 43% reduction in the risk of amputation or death from peripheral
vascular disease. These are valuable outcomes. Just how valuable is shown in Table
1 (adapted from Caro JJ et al).4
There are recognized benchmarks for diabetes care.5 How many patients with
diabetes achieve the recommended goals? NHANES (National Health and Nutrition
Examination Survey) data collected from 1999-2000 shows that 63% of patients
have not achieved a HgbA1C < 7% and that only 7% of patients in this national
survey had achieved a combination of HgbA1C < 7%, blood pressure <130/80 mm
Hg and total cholesterol <200 mg/dl.6

Table 1. The costs over 30 years from the
complications of uncontrolled type 2 diabetes
Hemoglobin A1C (%)
7.5
8
8.5
9

Average Blood Glucose (mg/dl)

30 Year Cost ($)

165
180
195
210

40,801
44,145
47,943
51,554
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Clearly this is a problem for patients, physicians and payers. The tools to achieve
positive outcomes in diabetes care exist; the problem is underutilization. Diabetes
education, patient self-management and promoting lifestyle changes are important
tools in the battle against glucose toxicity. However, the use of these tools in daily
practice is labor intensive.
The next critical step in diabetes care is to create the incentives that foster enhanced
utilization of these tools. But, are payers ready to recognize the value of diabetes
care? Are payers ready to take a long-term view of their mission and recognize the
value of preventing diabetic complications? Are payers ready to establish
reimbursement levels that are commensurate with the value of prevention? Is it
unreasonable to insist on incentives that recognize the long-term value of quality
care?
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